TRIUMPH and TRANSCEND records describe assigned clinical-trial arms and protocol-controlled procedures carried out by study teams. This FAQ reports those designs in the third person. It does not convert them into clicks, product quantities, administration steps, missed-dose instructions, personal schedules, or procurement recommendations.
What This FAQ Covers
Retatrutide remains investigational. Published and registered studies disclose multiple exposure arms, escalation periods, dose holds, reductions and discontinuations. Those facts help readers interpret outcomes and tolerability across trial arms; they do not establish a use protocol for a Remy Peptides research product.
They represent assigned exposure arms in registered clinical studies managed under sponsor protocols and study-team oversight. They are trial-design evidence, not a product-use schedule.
Published and registered Phase 3 materials describe 4mg, 9mg, and 12mg maintenance arms. Those values should be read only in the context of the cited trial records.
The protocols used controlled escalation so investigators could monitor tolerability and apply sponsor-defined holds, reductions, or discontinuations. This is a description of study design, not a recommendation.
Those situations were governed by each registered protocol and the responsible study team. This page does not translate trial rules into instructions for use outside a study.
No. It does not provide click conversions, split administrations, pen-duration estimates, protocol quantities, or ordering calculations.
Current lot documentation, device documentation, and an authorised institutional laboratory SOP control calibration, compatible accessories, handling and disposal. Trial-arm figures do not control a commercial research device.
Cross-trial comparisons require caution because populations, durations, estimands, background care and protocol designs differ. Direct head-to-head evidence is stronger than comparing separate studies.
No. Retatrutide remains investigational, and Remy Peptides supplies its listed materials for in-vitro laboratory research only, not for human or veterinary use.
Our Research Standards
This page distinguishes primary trial records from product documentation and does not treat a clinical-study schedule as product-use guidance. Read our research standards →
Primary Sources
ClinicalTrials.gov. TRIUMPH-1 study record. NCT05929066.
ClinicalTrials.gov. TRIUMPH-4 study record. NCT05931367.
Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023. doi:10.1056/NEJMoa2301972.
Eli Lilly and Company. TRIUMPH-1 Phase 3 topline results, May 21, 2026. investor.lilly.com.